• ESS Tech, Inc. (NYSE:GWH) surged by 166.24% due to a new collaboration in renewable energy storage.
• Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw a 155.48% increase, possibly driven by positive clinical trial results.
• Safe & Green Holdings Corp. (NASDAQ:SGBX) climbed 88.73% after regaining Nasdaq compliance and restructuring.

In recent market movements, several companies have shown significant price changes, reflecting various underlying factors such as company developments, industry trends, and broader economic conditions. Here's an analysis of the top gainers based on the provided data:

ESS Tech, Inc. (NYSE:GWH) has seen its stock price surge to $4.57, marking a remarkable increase of 166.24%. This jump is attributed to the growing demand for renewable energy storage solutions. The company recently announced a collaboration with Salt River Project to introduce Project New Horizon, a five megawatt, 50 megawatt-hour battery system. This partnership likely fueled investor interest, as highlighted by the trading volume spike to 245,639,308.

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) experienced a substantial price increase to $20.84, a 155.48% rise. This could be related to promising clinical trial results or regulatory approvals for its lead products, such as QRX003 for Netherton Syndrome. Despite a downturn in U.S. stocks, Quoin Pharmaceuticals saw a significant increase in its share price, indicating strong investor confidence.

Safe & Green Holdings Corp. (NASDAQ:SGBX) witnessed its stock price climb to $6.11, an 88.73% increase. The company regained compliance with all Nasdaq listing requirements as of October 3, 2025, through a restructuring deal with Boral and a reverse stock split. This move strengthened its capital structure and reduced dilution by over 80%, boosting investor confidence.

ESS Tech, Inc. Warrants (NYSE:GWH-WT) have also seen a notable price increase to $0.15, up by 61.69%. This mirrors the positive sentiment surrounding the parent company, ESS Tech, Inc., and suggests that investors are optimistic about the company's long-term prospects, especially with the new collaboration with Salt River Project.

enGene Holdings Inc. Warrants (NASDAQ:ENGNW) increased to $1.13, a 56.94% rise. This reflects investor optimism towards the company's pipeline, particularly its lead product candidate, EG-70, for treating bladder cancer. The biotechnology sector's focus on genetic medicines continues to attract investor interest.

These movements highlight the dynamic nature of the stock market, where company-specific developments, industry trends, and broader economic factors can significantly impact stock prices. Investors seem particularly keen on companies involved in renewable energy, biotechnology, and sustainable construction, reflecting broader market trends towards these sectors.